A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV

Optimization of antiretroviral therapy and anti-inflammatory treatments, such as statins, are among the strategies aimed at reducing metabolic disorders, inflammation and immune activation in people living with HIV (PLWH). We evaluated the potential benefit of combining both strategies. Forty-two PL...

Descripción completa

Detalles Bibliográficos
Autores: Negredo Puigmal, Eugènia|||0000-0001-5298-1734, Jiménez, Montse, Puig, Jordi|||0000-0002-4075-0346, Loste, Cora, Pérez-Álvarez, Núria|||0000-0001-6582-1553, Urrea, Víctor|||0000-0002-2577-856X, Echeverría, Patricia|||0000-0003-2755-3695, Bonjoch, Anna|||0000-0002-5343-2881, Clotet Sala, Bonaventura|||0000-0003-3232-4598, Blanco, Julià|||0000-0002-2225-0217
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:252911
Acceso en línea:https://ddd.uab.cat/record/252911
https://dx.doi.org/urn:doi:10.1371/journal.pone.0238575
Access Level:acceso abierto
id ES_251cb9cd4cc77bd1b729bea9749cb2cc
oai_identifier_str oai:ddd.uab.cat:252911
network_acronym_str ES
network_name_str España
repository_id_str
spelling A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIVNegredo Puigmal, Eugènia|||0000-0001-5298-1734Jiménez, MontsePuig, Jordi|||0000-0002-4075-0346Loste, CoraPérez-Álvarez, Núria|||0000-0001-6582-1553Urrea, Víctor|||0000-0002-2577-856XEcheverría, Patricia|||0000-0003-2755-3695Bonjoch, Anna|||0000-0002-5343-2881Clotet Sala, Bonaventura|||0000-0003-3232-4598Blanco, Julià|||0000-0002-2225-0217Optimization of antiretroviral therapy and anti-inflammatory treatments, such as statins, are among the strategies aimed at reducing metabolic disorders, inflammation and immune activation in people living with HIV (PLWH). We evaluated the potential benefit of combining both strategies. Forty-two PLWH aged ≥40 years receiving a protease inhibitor (PI)-based regimen were randomized (1:1) to switch from PI to Raltegravir (n = 20), or to remain on PI (n = 22). After 24 weeks, all patients received atorvastatin 20mg/day for 48 weeks. We analyzed plasma inflammatory as well as T-cell maturation, activation, exhaustion and senescence markers at baseline, 24 and 72 weeks, Plasma inflammatory markers remained unchanged. Furthermore, no major changes on T-cell maturation subsets, immunoactivation, exhaustion or immunosenescence markers in both CD4 and CD8 T cell compartments were observed. Only a modest decrease in the frequency of CD38 + CD8 T cells and an increase in the frequency of CD28 - CD57 + in both CD4 and CD8 T-cell compartments were noticed in the Raltegravir-switched group. The study combined antiretroviral switch to Raltegravir and Statin-based anti-inflammatory strategies to reduce inflammation and chronic immune activation in PLWH. Although this combination was safe and well tolerated, it had minimal impact on inflammatory and immunological markers. 22020-01-0120202020-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/252911https://dx.doi.org/urn:doi:10.1371/journal.pone.0238575reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2529112026-06-06T12:50:31Z
dc.title.none.fl_str_mv A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
title A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
spellingShingle A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
Negredo Puigmal, Eugènia|||0000-0001-5298-1734
title_short A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
title_full A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
title_fullStr A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
title_full_unstemmed A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
title_sort A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
dc.creator.none.fl_str_mv Negredo Puigmal, Eugènia|||0000-0001-5298-1734
Jiménez, Montse
Puig, Jordi|||0000-0002-4075-0346
Loste, Cora
Pérez-Álvarez, Núria|||0000-0001-6582-1553
Urrea, Víctor|||0000-0002-2577-856X
Echeverría, Patricia|||0000-0003-2755-3695
Bonjoch, Anna|||0000-0002-5343-2881
Clotet Sala, Bonaventura|||0000-0003-3232-4598
Blanco, Julià|||0000-0002-2225-0217
author Negredo Puigmal, Eugènia|||0000-0001-5298-1734
author_facet Negredo Puigmal, Eugènia|||0000-0001-5298-1734
Jiménez, Montse
Puig, Jordi|||0000-0002-4075-0346
Loste, Cora
Pérez-Álvarez, Núria|||0000-0001-6582-1553
Urrea, Víctor|||0000-0002-2577-856X
Echeverría, Patricia|||0000-0003-2755-3695
Bonjoch, Anna|||0000-0002-5343-2881
Clotet Sala, Bonaventura|||0000-0003-3232-4598
Blanco, Julià|||0000-0002-2225-0217
author_role author
author2 Jiménez, Montse
Puig, Jordi|||0000-0002-4075-0346
Loste, Cora
Pérez-Álvarez, Núria|||0000-0001-6582-1553
Urrea, Víctor|||0000-0002-2577-856X
Echeverría, Patricia|||0000-0003-2755-3695
Bonjoch, Anna|||0000-0002-5343-2881
Clotet Sala, Bonaventura|||0000-0003-3232-4598
Blanco, Julià|||0000-0002-2225-0217
author2_role author
author
author
author
author
author
author
author
author
description Optimization of antiretroviral therapy and anti-inflammatory treatments, such as statins, are among the strategies aimed at reducing metabolic disorders, inflammation and immune activation in people living with HIV (PLWH). We evaluated the potential benefit of combining both strategies. Forty-two PLWH aged ≥40 years receiving a protease inhibitor (PI)-based regimen were randomized (1:1) to switch from PI to Raltegravir (n = 20), or to remain on PI (n = 22). After 24 weeks, all patients received atorvastatin 20mg/day for 48 weeks. We analyzed plasma inflammatory as well as T-cell maturation, activation, exhaustion and senescence markers at baseline, 24 and 72 weeks, Plasma inflammatory markers remained unchanged. Furthermore, no major changes on T-cell maturation subsets, immunoactivation, exhaustion or immunosenescence markers in both CD4 and CD8 T cell compartments were observed. Only a modest decrease in the frequency of CD38 + CD8 T cells and an increase in the frequency of CD28 - CD57 + in both CD4 and CD8 T-cell compartments were noticed in the Raltegravir-switched group. The study combined antiretroviral switch to Raltegravir and Statin-based anti-inflammatory strategies to reduce inflammation and chronic immune activation in PLWH. Although this combination was safe and well tolerated, it had minimal impact on inflammatory and immunological markers.
publishDate 2020
dc.date.none.fl_str_mv 2
2020-01-01
2020
2020-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/252911
https://dx.doi.org/urn:doi:10.1371/journal.pone.0238575
url https://ddd.uab.cat/record/252911
https://dx.doi.org/urn:doi:10.1371/journal.pone.0238575
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404738339995648
score 15,301629

Similares en LA Referencia